These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 8825412)

  • 41. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.
    Kobayashi T; Ruan S; Clodi K; Kliche KO; Shiku H; Andreeff M; Zhang W
    Oncogene; 1998 Mar; 16(12):1587-91. PubMed ID: 9569026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The expression of oncogenes in tumour tissues of breast carcinoma patients.
    Rzymowska J; Grzybowska-Szatkowska L
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():93-5. PubMed ID: 11820644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bcl-2 family proteins and leukemia. Minireview.
    Kusenda J
    Neoplasma; 1998; 45(3):117-22. PubMed ID: 9717521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suppression activity of pro-apoptotic gene products in cancer cells, a potential application for cancer gene therapy.
    Lin J; Page C; Jin X; Sethi AO; Patel R; Nunez G
    Anticancer Res; 2001; 21(2A):831-9. PubMed ID: 11396172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of the antiapoptotic protein bcl-2 is not dependent on the tumor suppressor p53 protein in Indian breast carcinoma.
    Kesari AL; Chellam VG; Madhavan J; Nair PP; Nair MK; Pillai MR
    Pathobiology; 1997; 65(2):108-12. PubMed ID: 9253035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting cancer cell death with a bcl-XS adenovirus.
    Han JS; Núñez G; Wicha MS; Clarke MF
    Springer Semin Immunopathol; 1998; 19(3):279-88. PubMed ID: 9580270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research.
    Strasser A; O'Connor L; Huang DC; O'Reilly LA; Stanley ML; Bath ML; Adams JM; Cory S; Harris AW
    Behring Inst Mitt; 1996 Oct; (97):101-17. PubMed ID: 8950469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bcl-2 family proteins.
    Reed JC
    Oncogene; 1998 Dec; 17(25):3225-36. PubMed ID: 9916985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer.
    Thomadaki H; Scorilas A
    Crit Rev Clin Lab Sci; 2006; 43(1):1-67. PubMed ID: 16531274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. bcl-2: antidote for cell death.
    Tsujimoto Y
    Prog Mol Subcell Biol; 1996; 16():72-86. PubMed ID: 8822793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bcl-B: an "unknown" protein of the Bcl-2 family.
    Pervushin NV; Kopeina GS; Zhivotovsky B
    Biol Direct; 2023 Oct; 18(1):69. PubMed ID: 37899453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of apoptosis avoidance in cancer.
    Reed JC
    Curr Opin Oncol; 1999 Jan; 11(1):68-75. PubMed ID: 9914881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy.
    García-Aranda M; Pérez-Ruiz E; Redondo M
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544835
    [No Abstract]   [Full Text] [Related]  

  • 56. Bcl-2-family proteins and hematologic malignancies: history and future prospects.
    Reed JC
    Blood; 2008 Apr; 111(7):3322-30. PubMed ID: 18362212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In silico investigation of nonsynonymous single nucleotide polymorphisms in BCL2 apoptosis regulator gene to design novel protein-based drugs against cancer.
    Fareed MM; Dutta K; Dandekar T; Tarabonda H; Skorb EV; Shityakov S
    J Cell Biochem; 2022 Dec; 123(12):2044-2056. PubMed ID: 36146908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell death and cancer therapy.
    Bunz F
    Curr Opin Pharmacol; 2001 Aug; 1(4):337-41. PubMed ID: 11710730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.
    Berger S; Procko E; Margineantu D; Lee EF; Shen BW; Zelter A; Silva DA; Chawla K; Herold MJ; Garnier JM; Johnson R; MacCoss MJ; Lessene G; Davis TN; Stayton PS; Stoddard BL; Fairlie WD; Hockenbery DM; Baker D
    Elife; 2016 Nov; 5():. PubMed ID: 27805565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia.
    Reed JC
    Vitam Horm; 1997; 53():99-138. PubMed ID: 9197179
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.